title: Altered homeostasis of CD4(+) FoxP3(+) regulatory T-cell subpopulations in systemic lupus erythematosus.
abstract: The role of naturally occurring regulatory T cells (Treg), known to be phenotypically heterogeneous, in controlling the expression of systemic lupus erythematosus (SLE) is incompletely defined. Therefore, different subpopulations of CD4(+) FoxP3(+) Tregs in patients with active or inactive SLE were investigated and compared with those of healthy subjects and patients with ankylosing spondylitis (AS). Characterization of different subsets of circulating CD4(+) FoxP3(+) Tregs was examined using flow cytometry. CD4(+) CD25(high) T cells were sorted and examined for suppressive activity in vitro. The results showed first that a significant decrease in the frequency of CD4(+) CD25(high) FoxP3(+) T cells was present in patients with active SLE (n = 58), compared with healthy controls (n = 36) and AS patients (n = 23). In contrast, the frequencies of CD25(low) FoxP3(+) and CD25(-) FoxP3(+) CD4(+) T cells were significantly increased in patients with active SLE by comparison with the control subjects. The elevation of these two putative Treg subpopulations was associated with lower plasma levels of complement C3 and C4 in patients with SLE. In addition, the ratios of the three subsets of CD4(+) FoxP3(+) Tregs versus effector T cells (CD4(+) CD25(+) FoxP3(-)) were inversely correlated with the titer of anti-double-stranded DNA IgG in patients with inactive, but not active, SLE. These results suggest that the pathogenesis of SLE may be associated with a defect in the homeostatic control of different Treg subsets.
authors.affiliation: Kaohsiung Medical University, Taiwan, China. jlsuen@kmu.edu.tw
authors.forename: Jau-Ling
authors.initials: JL
authors.lastname: Suen
authors.forename: Hsiao-Ting
authors.initials: HT
authors.lastname: Li
authors.forename: Yuh-Jyh
authors.initials: YJ
authors.lastname: Jong
authors.forename: Bor-Luen
authors.initials: BL
authors.lastname: Chiang
authors.forename: Jeng-Hsien
authors.initials: JH
authors.lastname: Yen
mesh_terms: D000328:Adult; D000368:Aged; D000974:Antibodies, Antinuclear / Q000097:blood; D049109:Cell Proliferation; D002478:Cells, Cultured; D004247:DNA / Q000276:immunology; D018450:Disease Progression; D005260:Female; D051858:Forkhead Transcription Factors / Q000032:analysis*; D006706:Homeostasis / Q000276:immunology; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood; D016130:Immunophenotyping; D053645:Interleukin-2 Receptor alpha Subunit / Q000097:blood; D008180:Lupus Erythematosus, Systemic / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D016176:T-Lymphocyte Subsets / Q000276:immunology*; D050378:T-Lymphocytes, Regulatory / Q000276:immunology*; D055815:Young Adult
chemical_list: D000974:Antibodies, Antinuclear; C418974:FOXP3 protein, human; D051858:Forkhead Transcription Factors; D007074:Immunoglobulin G; D053645:Interleukin-2 Receptor alpha Subunit; D004247:DNA
references.citation: J Immunol. 2001 Aug 1;167(3):1245-53
references.pmid: 11466340
references.citation: J Clin Invest. 2005 Nov;115(11):3276-84
references.pmid: 16211090
references.citation: J Immunol. 2005 Dec 15;175(12):8392-400
references.pmid: 16339581
references.citation: Nat Immunol. 2005 Dec;6(12):1219-27
references.pmid: 16244650
references.citation: Immunology. 2006 Feb;117(2):280-6
references.pmid: 16423064
references.citation: Proc Natl Acad Sci U S A. 2006 Apr 25;103(17):6659-64
references.pmid: 16617117
references.citation: Blood. 2006 May 15;107(10):3940-9
references.pmid: 16410445
references.citation: Br J Pharmacol. 2006 Jun;148(3):245-54
references.pmid: 16604091
references.citation: J Exp Med. 2006 Jul 10;203(7):1693-700
references.pmid: 16818676
references.citation: J Exp Med. 2006 Jul 10;203(7):1701-11
references.pmid: 16818678
references.citation: Immunol Rev. 2006 Aug;212:149-62
references.pmid: 16903912
references.citation: Blood. 2006 Nov 15;108(10):3371-8
references.pmid: 16868256
references.citation: J Immunol. 2007 Feb 15;178(4):2579-88
references.pmid: 17277168
references.citation: Nat Med. 2007 Nov;13(11):1299-307
references.pmid: 17922010
references.citation: J Exp Med. 2003 Dec 15;198(12):1875-86
references.pmid: 14676299
references.citation: Immunity. 2002 Feb;16(2):311-23
references.pmid: 11869690
references.citation: Immunity. 2002 Apr;16(4):535-46
references.pmid: 11970877
references.citation: Nat Rev Immunol. 2003 Mar;3(3):253-7
references.pmid: 12658273
references.citation: Curr Opin Rheumatol. 2003 Jul;15(4):430-5
references.pmid: 12819471
references.citation: J Autoimmun. 2003 Nov;21(3):273-6
references.pmid: 14599852
references.citation: Proc Natl Acad Sci U S A. 2003 Dec 9;100(25):15059-64
references.pmid: 14608036
references.citation: Scand J Immunol. 2004 Feb;59(2):198-202
references.pmid: 14871297
references.citation: J Exp Med. 2004 Apr 5;199(7):971-9
references.pmid: 15067033
references.citation: J Exp Med. 2004 May 3;199(9):1285-91
references.pmid: 15117972
references.citation: Arthritis Rheum. 2004 Sep;50(9):2775-85
references.pmid: 15457445
references.citation: J Immunol. 2004 Oct 15;173(8):5008-20
references.pmid: 15470044
references.citation: Ann N Y Acad Sci. 1997 Apr 5;815:1-14
references.pmid: 9186635
references.citation: Arthritis Rheum. 1997 Sep;40(9):1725
references.pmid: 9324032
references.citation: J Pharmacol Exp Ther. 1998 Jul;286(1):191-200
references.pmid: 9655860
references.citation: Hum Immunol. 2005 Jan;66(1):13-20
references.pmid: 15620457
references.citation: Nat Immunol. 2005 Apr;6(4):338-44
references.pmid: 15785759
references.citation: Nat Immunol. 2005 Apr;6(4):345-52
references.pmid: 15785760
references.citation: J Clin Invest. 2005 Jul;115(7):1953-62
references.pmid: 16007258
references.citation: Curr Opin Immunol. 2005 Dec;17(6):638-42
references.pmid: 16209918
references.citation: Nat Immunol. 2002 Feb;3(2):135-42
references.pmid: 11812990